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Abstract
The Cord Blood Working Group of the World Marrow Donor Association created a
survey for cord blood banks (CBBs) aimed to identify and understand the main tech-
nical procedures currently used by public CBBs worldwide regarding cord blood units
(CBUs) available for unrelated hematopoietic stem cell transplantation. These techni-
cal procedures include CBU collection, (pre-) processing, packaging, testing, storage
and transport. The survey was an online survey created with SurveyGizmo and was
completed individually by each CBB at the end of 2017. The information is valuable
to transplant centers, CBBs as well as the global industry of public cord blood bank-
ing. In general, we can conclude from this survey that the majority of CBBs are up to
standard in terms of CBB technologies. Areas of improvement include accreditation,
increase standardization in testing and setting of total nucleated cells thresholds for
acceptance a CBU for public use. Furthermore, there is a need for a consensus in the
way CBBs operate in term of reservation and release to facilitate a more straightfor-
ward access to the therapy.
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1 | INTRODUCTION
Since the first cord blood unit (CBU) transplantation in 19891 over
50 000 CBUs have been shipped worldwide for unrelated hematopoietic
stem cell transplantation (HSCT).2 In 2018, 21% of the CBU shipments
for HSCT were transported between countries.2 However, not all cord
blood banks (CBBs) operate in a similar way. In recent years, besides the
usual CBU parameters of interest, transplant centers (TCs) are increas-
ingly looking for technical details of procedures. In this way, the TC can
make the best informed decision in choosing the right CBU for their
patient, especially when choosing a CBU from another country.
The Cord Blood Working Group (CBWG) of the World Marrow
Donor Association (WMDA) created a survey to gather information
specifically from cord blood banks with this in mind. With this survey,
the authors aimed to identify and understand the main technical proce-
dures currently used by public CBBs worldwide regarding CBUs avail-
able for unrelated HSCT. These technical procedures include CBU
collection, (pre-) processing, packaging, testing, storage, and transport.
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The information gathered with this survey serves multiple
purposes:
1. The information is valuable to TCs—as they are increasingly inter-
ested in characteristics of the CBBs themselves, in addition to
information about a specific CBU.
2. The information is valuable to the CBBs—as information they can
use to compare practices and perhaps improve processes at their
individual centers.
3. The information is valuable as a description of the global industry
of public cord blood (CB) banking.
The first two points are addressed with an overview of the results
of each responding CBB individually and is publicly available on the
WMDA's online collaborative tool.3 With this article, the authors
attempt to address the latter point.
2 | MATERIALS AND METHODS
The survey, entitled “Cord Blood Bank Technology Survey,” was an
online survey and was completed individually by each CBB at the end
of 2017. SurveyGizmo was used as the online tool to create the sur-
vey. Donor registries were asked to forward the survey to their net-
work CBBs and monitor to be sure they were completed. Only public
CBBs with CBUs available for unrelated HSCT were invited to com-
plete the survey. This original project was strongly supported by
NetCord (part of WMDA since 2017), as it is in line with its commit-
ment to provide high quality CB products to the transplant commu-
nity. Therefore, NetCord members were encouraged to actively
contribute. A copy of the complete survey can be found in the
Supporting Information.
Significance statement
In this brief report, we aim to identify and understand the
main technical procedures currently used by public cord
blood banks worldwide. The data were provided to World
Marrow Donor Association by surveying cord blood banks
directly and represent a true global effort to serve the cord
blood banking community. In this brief report, we identify
areas of improvement in the way cord blood banks operate
to facilitate a more straightforward access to the therapy.
GRAPH 1 Number of cord blood banks
participating per country
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3 | RESULTS
Provided are the most important findings from the survey presented
as key indicators with the percentage of CBBs and percentage of total
CBUs in current inventory (as of 2017) complying with those indica-
tors. The key indicators are considered critical or informative
depending on the importance to TCs. If applicable, the related FACT
(Foundation for the Accreditation of Cellular Therapy) standards are
referenced. The sixth edition of the FACT standards were used for
cross reference, since this was the version operational at the time the
survey was conducted.4 The authors choose to only include the refer-
ences to the FACT standards over other accrediting agencies like
AABB because they are the most extensive standards in the field. The
presented key indicators should not be considered as optimal
standards, like those developed by accrediting agencies. They rather
give a valuable description of the global industry of public CB banking.
One hundred and thirty-one CBBs in 41 different countries were
approached for participation and 77 CBBs in 31 countries completed
the survey (Graph 1). Therefore, the response rate of this survey
is 59%.
Eighty-eight percent of the responding CBBs are affiliated with a
national donor registry. The majority of the participating CBBs started
collecting CBUs before 2006 (77%). Inventory size of the CBBs varies
widely, with a median (range) inventory of 4224 (33-60 563) CBUs.
The total number of CBUs in inventory of all responding CBBs was
590 877, which was 78% of the total worldwide inventory2 at that
time. Only 17% of the total inventory comprise of CBUs with total
nucleated cells (TNC) over 150x10E7. These numbers are similar
TABLE 1 General data and accreditations
General data
Key indicators % of CBBs
% of CBUs
in worldwide
inventory Related FACT standard Critical or informative
Currently listing CBUs in WMDA
search and match service
94% 93% Part B: CBB Operational Standards
B1.3; B1.4; B3.1; B3.3; B5.3; B11.7;
B11.8





Current processing method is
plasma and RBC reduced
(automatic or manual)
93% NA Part D: CB Processing
D3.2.8
Critical
Inventory of CBUs stored for
unrelated patients with TNC
>150 (×10E7)
NA 17% Appendix V: Specification
Requirements for CBU Stored for
Clinical Use
Informative
Accreditations, licenses, certifications of the CBB
Key indicators % of CBBs % of CBUs in worldwide inventory Related FACT standard
Critical or
informative
FACT accredited 50% 69% (CBUs banked in a FACT
accredited CBB)






AABB accredited 19% 27% (CBUs banked in an AABB
accredited CBB)
Part B: CBB Operational
Standards. B1.2.1




88%a NA Part B: CBB Operational
Standards
B1.2.1; B5.7
Part D: CB Processing. D1.1
Critical
On-site inspection by national
donor registry
36% NA Accreditation section, page 2 Critical
Abbreviations: CB, cord blood; CBB(s), cord blood bank(s); CBU(s), cord blood unit(s); FACT, Foundation for the Accreditation of Cellular Therapy; NA, not
applicable; RBC, red blood cell reduced, TNC, total nucleated cells; WMDA, World Marrow Donor Association.
aOf the remaining 12%, nine CBBs reported having FACT and/or AABB accreditation and three CBBs reported having other licenses/accreditations/
certifications.
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TABLE 2 CBU collection to processing and current testing on cryopreserved CBU
CBU collection
Key indicators % of CBBs Related FACT standard Critical or informative
Current CBU collection Part C: CB Donor Management and Collection. C6.2 Informative
In utero: 53%
Ex utero: 13%
CBB uses both methods: 34%
Conditioning and transport from collection center to CBB
Key indicators % of CBBs Related FACT standard Critical or informative
Use of secondary bag (to contain any leakage) 82% Part C: CB Donor Management and Collection. C7.3 Critical
Refrigerated transporta Part C: CB Donor Management and Collection. C7.5 Critical
Active: 10%
Passive: 56%
Temperature probea Part C: CB Donor Management and Collection. C7.5 Critical
Electronic: 70%
Nonelectronic: 10%
Qualified transport 78% Part C: CB Donor Management and Collection. C7.5 Critical
Define a validated temperature 96% Part C: CB Donor Management and Collection. C7.5 Critical
Preprocessing evaluation—current threshold for accepting a CBU for public use
Key indicators
%
of CBBs Related FACT standard
Critical or
informative
TNC >125 (×10E7) 60% Informative
Performed % viability CD45 positive cells 36% Part D: CB Processing
D.3.2.4; D3.2.4.1
Informative
Performed % viability CD34 positive cells 40% Informative
Collection report 100% Part C: CB Donor Management and Collection. C5;
C7.7
Critical
Informed consent 100% Part C: CB Donor Management and Collection. C4 Critical
Temperature + integrity of the bag 97% Part D: CB Processing
D5; D5.3; D6; D6.5
Critical
Medical history 96% Part C: CB Donor Management and Collection. C5 Critical
Maternal IDM results 70% Part D: CB Processing
D10
Appendix IV: Testing Requirements
Critical
ISHAGE guidelines for CD34 enumeration method 91% Informative




Perform postprocessing/prefreeze CD34 cell
count
93% Appendix IV: Testing Requirements Critical
<48 hours from collecting to processing 97% Part D: CB Processing
D3; D3.2.6
Critical
Processing and CBU storage
Key indicators % of CBBs Related FACT standard Critical or informative
Current automatic prefreeze processing method Part D: CB Processing
D3.2
Critical
AXP, SEPAX, Optipress, Macropress (and/or): 75%
Manual processing only: 24%
No processing: 1%
Current cryopreservation methoda,b Part D: CB Processing
D5: Cryopreservation
Critical
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TABLE 2 (Continued)
Processing and CBU storage
Key indicators % of CBBs Related FACT standard Critical or informative
Conventional controlled rate freezers: 76%
Bioarchive only: 21%
Packaging when a unit is stored D5: Cryopreservation
D5.3
Informative
Metal canister only: 32%
Overwrap only: 1%
Both: 67%
At least two segments stored with the unit 95% D4: Samples
D4.1.1
Critical
Current testing on cryopreserved CBU
Key indicators % of CBBs Related FACT standard
Critical or
informative
Standard on maternal sample D10: Maternal Testing
D10.1; Appendix IV; Testing
Requirements
Critical
HIV 1/2 antibodies and/or HIV 1 and 2 + 0 antibodies: 100%
HIV NAT: 84%
Standard on maternal sample D10: Maternal Testing
D10.1; Appendix IV; Testing
Requirements
Critical
Hepatitis B surface antigen: 100%
Hepatitis B core antibody: 88%
HBV NAT: 83%
Standard on maternal sample D10: Maternal Testing
D10.1; Appendix IV; Testing
Requirements
Critical
Hepatitis C antibody: 100%
HCV NAT: 84%
Standard HTLV 1/2 antibodies on maternal sample 88% D10: Maternal Testing
D10.1; Appendix IV; Testing
Requirements
Critical
Standard CMV on maternal sample 96% D10: Maternal Testing
D10.1; D10.2; D10.3; Appendix IV;
Testing Requirements
Informative
Standard syphilis on maternal sample 100% D10: Maternal Testing
D10.1; D10.3.2; Appendix IV; Testing
Requirements
Critical
At least extra storage of plasma and material for DNA extraction of




HLA-A HR typing at time of listing 54% D9: CBU Testing
D.9.3.3; Appendix IV; Testing
Requirements
Critical
HLA-B HR typing at time of listing 54% D9: CBU Testing
D.9.3.3; Appendix IV; Testing
Requirements
Critical
HLA-DRB1 HR typing at time of listing 79% D9: CBU Testing
D.9.3.3; Appendix IV; Testing
Requirements
Critical
HLA-C at least LR typing at time of listing 100% D9: CBU Testing
D.9.3.3; Appendix IV; Testing
Requirements
Critical







≥1.25 CD34 (×10E6) single platform threshold for accepting a CBU






D9: CBU Testing Critical
(Continues)
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compared with the TNC of CBU inventory available in the interna-
tional database of WMDA search and match service.2
The most important findings are summarized in Tables 1-3.
4 | DISCUSSION
Although 88% of the participating CBBs report to be licensed by a
competent authority, only 50% report to have FACT accreditation and
19% have AABB accreditation. As discussed in three recent papers by
Dehn et al,5 the Cord Blood Accociation,6 and Rocha,7 selection of
CBUs from CBBs that take part in long standing voluntary accredita-
tion programs has now been included in recommended CB selection
policies as a criterion to evaluate CBUs. Based on the results of our
survey, this appears to be an area where CBBs can make an effort to
improve.
Another recommended CB selection policy is to use RBC
depleted units.5 With 97% of the responding CBBs reporting they are
currently depleting units of RBC (either automatic or manually) it
looks like this is now standard practice around the world. Having an
attached segment for HLA confirmatory typing is also essential.5,6
Currently 95% of the responding CBBs have at least two attached
segments stored with the CBU.
Additionally, in the Cord Blood Association paper6 requirements
for infectious disease marker (IDM) testing are given. All tests should
be done on the maternal blood sample. Anti-HIV 1/2, Hepatitis C anti-
body, Syphilis and Hepatitis B surface antigen are required to be stan-
dard performed and 100% of CBBs report to perform these tests.
Anti-CMV Total/IgG/IgM is also required to be standard performed
and 96% of CBBs report to perform these. Anti-HTLV 1/2 is rec-
ommended to be standards performed and 88% of CBBs report to
perform this test.
Standards for CB donation do not require the need for a second
testing in main transmissible diseases and in this situation it becomes
critical to perform testing using NAT technologies. As shown in this
survey, there is a substantial number of CBBs that performed NAT
testing but still 16%-17% of the CBBs answering the questionnaire
are not routinely doing this analysis.
It is substandard that only 62% of the CBBs can ship a CBU in
1 week. This does not fulfill the concept that a CBU is an off-the-shelf
therapy. To improve the shipping speed, it would require international
harmonization between CBBs. Furthermore, there is not a good con-
sensus in when/how to do the release testing on an attached seg-
ment. This also generates a non-standardized result between CBBs.
This is a field where the CBBs need to work together to facilitate
access to the therapy.
Only 42% of CBBs answered they use a threshold of TNC
>100x10E7 for accepting a CBU for public use. The standards only
have instructions on how much TNC a CBU must contain at the end
of the process and only mention a CBB must have a policy in place to
verify it. From the survey results, it cannot be identified why a CBB
would bank CBU with low TNC counts knowing these are less likely
to be requested. In recent years it has become harder to sustain a suc-
cessful CBB and CBBs perhaps should consider only bank larger units
because they are most on demand.
The questions about testing thresholds for accepting a CBU for
public use (postprocessing) were answered in a wide range with many
CBBs answering not applicable or leaving the answer blank. Therefore,
this part of the questionnaire is inconclusive and difficult to interpret.
This could either be due to the fact that the questions were unclear
and difficult to fill out, or the fact that there is no consensus in the CBB
field on thresholds for these tests. Moreover, the FACT standards are
not specific about the time point in the CBB process pre-evaluation of
the CBU should take place. However, the information gained from
these questions about practices of pre-evaluation is still relevant for
CBBs to know about. It matters to the CBBs in terms of benchmarking,
self-evaluation and how a CBB defines which units are “bankable.”
A response rate of 59% is considered high for these types of sur-
veys, which indicates the commitment of the CBB community to
make this information available to TCs and other CBBs. One thing to
keep in mind is that these results were current at the end of 2017/
beginning of 2018. As the CBB field is fast moving, these data should
TABLE 2 (Continued)
Current testing on cryopreserved CBU
Key indicators % of CBBs Related FACT standard
Critical or
informative
≥1.25 CD34 (×10E6) double platform threshold for accepting a











Abbreviations: CB, cord blood; CBB(s), cord blood bank(s); CBU(s), cord blood unit(s); CMV, cytomegalovirus; DNA, deoxyribonucleic acid; FACS,
fluorescence-activated cell sorting; FACT, Foundation for the Accreditation of Cellular Therapy; HIV, human immunodeficiency viruses; HLA, human
leucocyte antigen; HR, high resolution; HTLV, human T-cell lymphotropic virus; IDM, infectious disease marker; ISHAGE, International Society for
Hematotherapy and Graft Engineering; LR, low resolution; NA, not applicable; NAT, nucleic acid testing; QC, quality control; TNC, total nucleated cells;
UNK, unknown.
aNot all answer categories are shown, therefore the percentage does not add up to 100%.
bMultiple answers were possible, therefore percentage does not add up to 100%.
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be closely monitored. Future directions of collecting this kind of data
needs to be aligned with the Netcord-FACT standards seventh edi-
tion. WMDA will collect a summarized version of this survey in 2020,
where CBBs can directly submit their data to the WMDA Share
website.3
5 | CONCLUSION
In general, we can conclude from this survey that the majority of pub-
lic CBBs are up to standard in terms of CBB technologies. Areas of
improvement could include accreditation, increase standardization in
TABLE 3 Storage, HLA typing, reservation policies and adverse event reporting
Storage of CBUs at the CBB
Key indicators % of CBBs % of CBUs in worldwide inventory Related FACT standard Critical or informative
Storage containera Informative
Bioarchive conventional: 30% 33%
Vapor phase conventional: 56% 58%
Liquid phase: 52% 57%
Double walled liquid nitrogen: 16% 16%
At least any storage monitoring 100% 100% D6.5: Conditions for Storage Critical















EFI lab: 51% 37%
ASHI lab: 36% 50%
No accredited lab: 13% 13%






% of CBUs in
worldwide
inventory Related FACT standard
Critical or
informative
Time to shipment less than 1 week after
order placed
62% NA Informative
Post-thaw testing of CD34, TNC cell counts,
% viability of CD34, CD45, and CFUsb
NA Appendix IV: Thawed segment or thawed representative
sample prior to release to the Clinical Program
Informative
At unit reservation or CT: 50%
When CBU shipment requested: 22%
Cancelation feeb
Never: 52% NA Informative





% of CBUs in worldwide
inventory Related FACT standard
Critical or
informative
Adverse event reporting to competent
authority
74% NA B2: Quality Management
B2.1; B5.10
Part C: CB Donor Management and
Collections
C5.1; C6.9
E7: Clinical Outcome Data
E7.1
Critical
Abbreviations: ASHI, American Society for Histocompatibility and Immunogenetics; CB, cord blood; CBB(s), cord blood bank(s); CBU(s), cord blood unit(s);
CFUs, colony forming units; CT, confirmatory typing; EFI, European Federation for Immunogenetics; FACT, Foundation for the Accreditation of Cellular
Therapy; HLA, human leucocyte antigen; NA, not applicable; TNC, total nucleated cells.
aMultiple answers were possible, therefore percentage does not add up to 100%.
bNot all answer categories are shown, therefore the percentage does not add up to 100%.
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testing and setting of TNC thresholds for acceptance a CBU for public
use. Furthermore, there is a need for a consensus in the way CBBs
operate in term of reservation and release to facilitate a more straight-
forward access to the therapy.
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